Novel intravesical gemcitabine delivery system (TAR-200) for neoadjuvant treatment of MIBC: context is everything

被引：0
|
作者：
Katherine M. Rodriguez
Max Kates
机构：
[1] Brady Urological Institute,
[2] Johns Hopkins Medicine,undefined
[3] The Greenberg Bladder Cancer Institute & James Buchanan Brady Urological Institute,undefined
[4] Johns Hopkins Medicine,undefined
来源：
Nature Reviews Urology | 2022年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Muscle-invasive bladder cancer (MIBC) remains a deadly disease, despite aggressive surgical and systemic chemotherapeutic treatments. New treatment modalities are needed. A novel intravesicle drug delivery device for neoadjuvant treatment of MIBC has been developed, and preliminary results on the efficacy and safety of this system are available.
引用
收藏
页码：579 / 580
页数：1
相关论文
共 11 条
  • [1] Novel intravesical gemcitabine delivery system (TAR-200) for neoadjuvant treatment of MIBC: context is everything
    Rodriguez, Katherine M.
    Kates, Max
    NATURE REVIEWS UROLOGY, 2022, 19 (10) : 579 - 580
  • [2] TAR-200: Investigational intravesical drug delivery system for bladder cancer
    Munavvir, Muhammed
    Mujeeburahiman, M.
    Khan, Altaf
    Das Debashish, Gaurav
    UROLOGIA JOURNAL, 2025,
  • [3] Effect of Gem RIS (gemcitabine-releasing intravesical system, TAR-200) on antitumor activity in muscle-invasive bladder cancer (MIBC)
    Daneshmand, Siamak
    Pohar, Kamal S.
    Steinberg, Gary D.
    Aron, Manju
    Cutie, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial
    Daneshmand, Siamak
    Brummelhuis, Iris S. G.
    Pohar, Kamal S.
    Steinberg, Gary D.
    Aron, Manju
    Cutie, Christopher J.
    Keegan, Kirk A.
    Maffeo, John C.
    Reynolds, Donald L.
    Raybold, Bradley
    Chau, Albert
    Witjes, J. Alfred
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (07) : 344.e1 - 344.e9
  • [5] PENELOPE: TISSUE PENETRATION OF GEMCITABINE PHOSPHATE METABOLITES FOLLOWING TAR-200 ADMINISTRATION VS STANDARD INTRAVESICAL INSTILLATION IN MINIPIGS
    Siamak, Daneshmand
    Koen, Wuyts
    De, Meulder Marc
    Liesbeth, Vereyken
    Van, Heerden Marjolein
    Herman, Borghys
    Geert, Mannens
    Karen, Daniel
    Samuel, Spigelman
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [6] SunRISe-4: TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant platinum-based chemotherapy.
    Psutka, Sarah P.
    Cutie, Christopher
    Bhanvadia, Sumeet Kaur
    Keegan, Kirk A.
    Crist, Wendy
    Tian, Shaozhou Ken
    Maffeo, John
    Raybold, Bradley
    Kashmer, Marietta
    Hasan, Mohamad
    Li, Xiang
    Beeharry, Neil
    Thomas, Shibu
    Tian, Hui
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b Study
    van Valenberg, F. Johannes P.
    van der Heijden, Antoine G.
    Cutie, Christopher J.
    Bhanvadia, Sumeet
    Keegan, Kirk A.
    Hampras, Shalaka
    Sweiti, Hussein
    Maffeo, John C.
    Jin, Shu
    Chau, Albert
    Reynolds, Donald L.
    Iarossi, Crysti
    Kelley, April
    Li, Xiang
    Stromberg, Katharine A.
    Sedelaar, J. P. Michiel
    Steenbruggen, Jessica J. O.
    Somford, Diederik M.
    Witjes, J. Alfred
    EUROPEAN JOURNAL OF OPERATIONAL RESEARCH, 2024, 62 (01) : 8 - 15
  • [8] TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4)
    Necchi, A.
    Guerrero-Ramos, F.
    Crispen, P. L.
    Imbroda, B. Herrera
    Garje, R.
    Powles, T. B.
    Peyton, C. C.
    Pradere, B.
    Ku, J. H.
    Shore, N. D.
    Boegemann, M.
    Preston, M. A.
    Xylinas, E.
    Gong, C.
    Najmi, S.
    Hasan, M.
    Stitou, H.
    Bhanvadia, S.
    Sweiti, H.
    Psutka, S. P.
    ANNALS OF ONCOLOGY, 2024, 35 : 1271 - 1272
  • [9] Novel Tubeimoside I liposomal drug delivery system in combination with gemcitabine for the treatment of pancreatic cancer
    Li, Shuhui
    Liu, Yuansheng
    Sui, Xiaojun
    Zhuo, Yuzhen
    Siqi, He
    Sijia, Zhang
    Hui, Zhang
    Dihua, Li
    Dapeng, Zhang
    Lei, Yang
    NANOMEDICINE, 2024, 19 (24) : 1977 - 1993
  • [10] Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: Phase 1 first-inhuman study.
    Vilaseca, Antoni
    Guerrero, Felix
    Zainfeld, Daniel
    Shore, Neal D.
    Rodriguez Faba, Oscar
    Meijer, Richard P.
    Alfred Witjes, Alfred
    Jackson McRee, Autumn
    Kalota, Anna
    Stone, Nicole L.
    David Lauring, Josh
    Zhu, Wei
    Beeharry, Neil
    O'Dondi, Lang A.
    Jayram, Gautam
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12